We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Infections can be reduced and patient quality of life can be improved by using antimicrobial wound care materials developed by Pertinax. In vitro studies have already been performed using the company's development across multiple applications.
days to go: Expired investment: £616,916
Please watch the video for more information
days to go: Expired investment: £607,175
During their stay in hospital, around 7-10% of patients attract unexpected infections. In some cases, this is caused by unclean complex surgical tools. Aspetium have developed ultrasonic washers (dubbed "uSonic") to thoroughly decontaminate expensive surgical instruments, which can be safely reused to potentially prevent easily avoidable infections.
days to go: Expired investment: £151,167
Antaco is a clean technology company that has come up with a solution to process any type of organic waste, both wet & dry (including woody), into a solid biofuel and a direct replacement for fossil coal. The company aims to disrupt current methods of organic waste disposal. Antaco won the 2013 Shell Springboard & 2014 WEX Technology Awards. It has received an £857,000 grant from the UK government and was voted the top UK & EU Cleantech start-up by Climate-KIC & EIT (European Institute of Technology & Innovation) in 2013. Antaco is seeking £400,000 (Future Fund matched) in further investment to expand operational capacity on-site, build its team, and capitalise on growing market opportunities.
days to go: Expired investment: £661,410
Pioneering medical device company with patented technologies in the "key hole" surgery market 
days to go: Expired investment: £600,083
Please watch the video for more information
days to go: Expired investment: £257,501
Accunea is the world’s first real-time continuous organ function monitoring company, specializing in biomarkers for kidney transplantation. Targeting NHS hospitals in the UK undertaking renal transplantation, the company aims to provide relief to patients awaiting organ transplants by ensuring availability of more organs for transplant and reducing the numbers of deaths due to increasing waiting list times. For this purpose, the company has designed a miniature analysis device which constantly monitors markers of kidney function and metabolism through a standard dribble line put into the vein of a patient. Accunea is raising £400,000 at a pre-money valuation of £2,230,000. The funds will be used to achieve clinical utility in Kidney and Pancreas.

Pitch Rated

71%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £388,038
Cardiovascular Disease is the leading cause of death in the UK, PlaqueTec have developed a Liquid Biopsy System, which allows cardiologists to gain further information from a patient's coronary artery and provide more effective treatment to those affected by the disease.
days to go: Expired investment: £1,493,593
Ultramed are a health tech company, placing patient experience and innovation at the forefront. They operate a suite of cloud based pre operative products by combining clinical NHS operative experience. The aim is to reduce costs increase health care resources.
days to go: Expired investment: £317,540
Qure’s aim is to provide individual healthcare that is both affordable and highly convenient, becoming the platform of choice for both patients and practitioners. Qure offer 24/7 private healthcare, without the huge price tag that is usually associated with these kinds of services. 
days to go: Expired investment: £1,162,206
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph